P. Sadaphal et al., Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis, CLIN INF D, 33(10), 2001, pp. 1687-1691
Treatment of latent Mycobacterium tuberculosis infection with isoniazid can
cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity
among persons coinfected with hepatitis C virus (HCV) is unknown. We conduc
ted a prospective study among 146 injection drug users with M. tuberculosis
infection and normal baseline hepatic transaminase values who were treated
with isoniazid. Of 146 participants, 138 (95%) were HCV-seropositive. Thir
ty-seven participants (25%) were human immunodeficiency virus (HIV)-seropos
itive. Thirty-two (22%; 95% confidence interval [CI], 16%-30%) of 146 parti
cipants developed transaminase value elevations to >3 times the upper limit
of normal. Transaminase value elevation was associated with concurrent alc
ohol use but not with race, age, presence of hepatitis B surface antigen, H
IV-1 infection, or current injection drug use. Isoniazid was withdrawn from
11 participants (8%; 95% CI, 4%-13%). Of 8 deaths during followup, none we
re attributed to isoniazid-associated hepatotoxicity. The risk of transamin
ase value elevation and drug discontinuation for HCV-infected persons recei
ving isoniazid was within the range reported for populations with lower HCV
prevalence.